| Payer perspective |
|
|
|
|
|
| No vaccination |
-0.001368 |
9.27 |
|
|
|
| Strategy A (V-MSD 12 mo/V-MSD 24 mo) |
-0.000364 |
22.21 |
0.001004 |
12.94 |
12 892.57 |
| Strategy B (V-GSK 12 mo/V-GSK 24 mo) |
-0.000388 |
22.58 |
0.000980 |
13.31 |
13 587.41 |
| Strategy C (V-MSD 15 mo/V-MSD 5.5 y) |
-0.000355 |
21.02 |
0.001012 |
11.75 |
11 607.80 |
| Strategy D (V-GSK 15 mo/V-GSK 5.5 y) |
-0.000393 |
21.21 |
0.000975 |
11.94 |
12 246.17 |
| Strategy E (V-MSD 15 mo/MMRV-MSD 5.5 y) |
-0.000355 |
24.16 |
0.001012 |
14.89 |
14 708.59 |
| Strategy F (V-GSK 15 mo/MMRV-GSK 5.5 y) |
-0.000393 |
24.17 |
0.000975 |
14.90 |
15 284.46 |
| Societal perspective |
|
|
|
|
|
| No vaccination |
-0.001368 |
88.94 |
|
|
|
| Strategy A (V-MSD 12 mo/V-MSD 24 mo) |
-0.000364 |
36.94 |
0.001004 |
-52.01 |
Dominant |
| Strategy B (V-GSK 12 mo/V-GSK 24 mo) |
-0.000388 |
41.46 |
0.000980 |
-47.48 |
Dominant |
| Strategy C (V-MSD 15 mo/V-MSD 5.5 y) |
-0.000355 |
34.63 |
0.001012 |
-54.31 |
Dominant |
| Strategy D (V-GSK 15 mo/V-GSK 5.5 y) |
-0.000393 |
41.09 |
0.000975 |
-47.85 |
Dominant |
| Strategy E (V-MSD 15 mo/MMRV-MSD 5.5 y) |
-0.000355 |
37.77 |
0.001012 |
-51.17 |
Dominant |
| Strategy F (V-GSK 15 mo/MMRV-GSK 5.5 y) |
-0.000393 |
44.06 |
0.000975 |
-44.89 |
Dominant |